BRIEF-Theratechnologies and partner evaluating steps to seek and obtain approval of 1 mg/vial presentation

Mon May 16, 2016 8:59am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

May 16 (Reuters) - Theratechnologies Inc

* Decided to withdraw marketing authorization application for registration of 2 mg/vial presentation of tesamorelin in Brazil

* Co and its partner are currently evaluating required steps to seek and obtain approval of 1 mg/vial presentation

* Decision by co, Sanofi based on receipt of questions asked by regulatory authority, ANVISA

* Decision by co, Sanofi also based on , fact that presentation is no longer available in any other territory Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)